免疫载药脂质体治疗小鼠泡球蚴

THE EXPERIMENTAL THERAPY WITH IMMUNOLIPOSOMECARRIED DRUG FOR ALVEOLAR HYDATIDS IN MICE

目的：观察载阿苯达唑（ABZ）的抗泡球蚴抗体的免疫脂质体对小鼠继发性泡球蚴病的疗效。方法：观察游离的、脂质体运载与免疫脂质体运载的ABZ（12．5、25和50mg／kg）对小鼠腹腔泡球蚴增殖的抑制。结果：免疫脂质体治疗抑制率高于脂质体，后者又高于游离ABZ，高剂量时3组抑制率分别为87．8％、65．2％和17.7％，组间比较差异显著（P＜0.01）；肝和腹腔泡球蚴摄取免疫脂质体的量比单纯脂质体高2．4倍（P＜0．01）。结论：免疫脂质体作载体可明显提高ABZ对泡球蚴病的疗效。

Objective:To investigate the therapeutic effect on mice alveolar hydatids of albendazole(ABZ)-carrying immunoliposome, which was covalently linked with monoclonal antibody against alveococcus. Methods: To measure the inhibitory effect on alveococcus growth of treatment with free-, liposome carried and immunoliposome carried ABZ (12. 5, 25 and 50 mg/kg). Results: The inhibitory ratesof immunoliposome were significantly higher than those of liposome, and the latter inhibitory rates weremarkedly higher than those of free drug. When treated with high dose ABZ (50 mg/kg), the inhibitoryrates in different groups were 87. 7%, 65. 2% and 17. 7%, respectively (P<0. 01, between groups).The amount of immunoliposome uptake by alveococcus in liver and peritoneum both were 2. 4-fold higher than those of 1iposome (P<0. 01).Conclusion: Immunoliposome, as a carrier, significantly potentates therapeutic effect of ABZ on alveolar hydatids.